The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare - there are only 2,500 cases diagnosed in the United States each year - about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades. To see more details visit, www.medicalnewstoday.com